Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Swiss National Science Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether in pre-hypertensive and hypertensive states such as white coat hypertension, obesity related hypertension or resistant hypertension, renal function is more sensitive to orthostatic stress.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control group | Active Comparator | healthy volunteer |
|
| obesity group | Active Comparator | Patients with BMI >30 Kg/m2 |
|
| white coat hypertension group | Active Comparator | Patients with office blood pressure >140/90 mmHg and ambulatory daytime blood pressure <135/85 mmHg |
|
| Resistant hypertension | Active Comparator | Patients with ambulatory blood pressure > 135/85 mm Hg (day) or >120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lower body negative pressure (LBNP) | Other | Lower limbs are put in in LBNP device for one hour (-30 mbar) |
|
| Measure | Description | Time Frame |
|---|---|---|
| sodium excretion | sodium excretion will be compared to control group (healthy volunteers) after one hour of lower negative pressure. The protocol includes 2 hours of baseline measure, one hour of lower negative pressure and 2 hours of recovery | after one hour of lower body negative pressure |
| Measure | Description | Time Frame |
|---|---|---|
| glomerular filtration rate | after one hour of lower body negative pressure |
| Measure | Description | Time Frame |
|---|---|---|
| renal plasma flow | after one hour of lower body negative pressure |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gregoire Wuerzner, MD | Centre Hospitalier Universitaire Vaudois | Principal Investigator |
| Michel Burnier, MD | Centre Hospitalier Universitaire Vaudois | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Service of nephrology and hypertension | Lausanne | Canton of Vaud | 1011 | Switzerland | ||
| Service of nephrology and hypertension |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33073631 | Derived | Vakilzadeh N, Petrovic D, Maillard M, Favre L, Grouzmann E, Wuerzner G. Impact of obesity with or without hypertension on systemic haemodynamic and renal responses to lower body negative pressure. Blood Press. 2021 Feb;30(1):67-74. doi: 10.1080/08037051.2020.1829963. Epub 2020 Oct 19. | |
| 29876358 | Derived | Vuignier Y, Grouzmann E, Muller O, Vakilzadeh N, Faouzi M, Maillard MP, Qanadli SD, Burnier M, Wuerzner G. Blood Pressure and Renal Responses to Orthostatic Stress Before and After Radiofrequency Renal Denervation in Patients with Resistant Hypertension. Front Cardiovasc Med. 2018 May 23;5:42. doi: 10.3389/fcvm.2018.00042. eCollection 2018. |
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 15, 2018 | |
| Reset | Oct 23, 2018 | |
| Release | Aug 31, 2023 | |
| Reset | Mar 14, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 15, 2018 | Oct 23, 2018 | |||
| Aug 31, 2023 |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D009765 | Obesity |
| D059466 | White Coat Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
Not provided
Not provided
| ID | Term |
|---|---|
| D008150 | Lower Body Negative Pressure |
| C077793 | candesartan cilexetil |
| ID | Term |
|---|---|
| D003664 | Decompression |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Candesartan cilexetil | Drug | candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group |
|
| Lausanne |
| 1011 |
| Switzerland |
| Mar 14, 2024 |
| D009748 |
| Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |